{"doi":"10.3390/ijms26073405","title":"Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis","abstract":"<jats:p>The relationship between telomere shortening and patients with chronic kidney disease (CKD) has recently been investigated. Although most patients respond adequately to erythropoiesis-stimulating agents (ESAs), approximately 10% do not, and this is referred to as ESA resistance. The aim of our study was to investigate the relationship between telomere shortening and erythropoietin resistance in patients with CKD on hemodialysis. This cross-sectional, comparative, analytical, and observational study was conducted in patients of both sexes over 18 years of age diagnosed with CKD. Two groups of patients were identified. The first group consisted of 40 patients receiving erythropoiesis-stimulating agents with erythropoietin resistance. The second group consisted of 40 patients with the same characteristics but without erythropoietin resistance. Telomere length was measured by real-time PCR. Eighty patients were included in the study. Mean hemoglobin levels were lower in the erythropoietin resistance group (8.8 ± 1.67 vs. 11.95 ± 1.81, p = 0.001). Differences were observed in hematocrit and albumin levels, which were lower in patients with erythropoietin resistance, while PTH levels were higher in this group (788 ± 538.47 vs. 535.65 ± 603.06, p = 0.001). A significant difference in telomere length (T/S) was observed between the two groups, with shorter telomere length in the erythropoietin resistance group (0.45 ± 0.04 vs. 0.56 ± 0.03, p = 0.01). Telomere shortening may be associated with anemia and erythropoietin resistance in patients with CKD undergoing hemodialysis. This relationship suggests the need to explore whether telomere length recovery improves the response to ESAs.</jats:p>","journal":"International Journal of Molecular Sciences","year":2025,"id":614147,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1582522,"name":"Marcos Javier Romero-Vázquez","orcid":"0009-0000-2520-602X","position":1,"is_corresponding":false},{"id":1582523,"name":"Angélica Jeanette Luevanos-Aguilera","orcid":"0000-0001-9230-3073","position":2,"is_corresponding":false},{"id":1582524,"name":"Paulina Monserrat Meza-Herrán","orcid":null,"position":3,"is_corresponding":false},{"id":1582525,"name":"Edna Montserrat Ramos-Rodriguez","orcid":null,"position":4,"is_corresponding":false},{"id":1582526,"name":"Sandra Martínez-Garza","orcid":null,"position":5,"is_corresponding":false},{"id":1582527,"name":"Mario Murguia-Perez","orcid":"0000-0003-4260-389X","position":6,"is_corresponding":false},{"id":1303232,"name":"Blanca Murillo-Ortíz","orcid":"0000-0003-4775-2755","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis","abstract":"<jats:p>The relationship between telomere shortening and patients with chronic kidney disease (CKD) has recently been investigated. Although most patients respond adequately to erythropoiesis-stimulating agents (ESAs), approximately 10% do not, and this is referred to as ESA resistance. The aim of our study was to investigate the relationship between telomere shortening and erythropoietin resistance in patients with CKD on hemodialysis. This cross-sectional, comparative, analytical, and observational study was conducted in patients of both sexes over 18 years of age diagnosed with CKD. Two groups of patients were identified. The first group consisted of 40 patients receiving erythropoiesis-stimulating agents with erythropoietin resistance. The second group consisted of 40 patients with the same characteristics but without erythropoietin resistance. Telomere length was measured by real-time PCR. Eighty patients were included in the study. Mean hemoglobin levels were lower in the erythropoietin resistance group (8.8 ± 1.67 vs. 11.95 ± 1.81, p = 0.001). Differences were observed in hematocrit and albumin levels, which were lower in patients with erythropoietin resistance, while PTH levels were higher in this group (788 ± 538.47 vs. 535.65 ± 603.06, p = 0.001). A significant difference in telomere length (T/S) was observed between the two groups, with shorter telomere length in the erythropoietin resistance group (0.45 ± 0.04 vs. 0.56 ± 0.03, p = 0.01). Telomere shortening may be associated with anemia and erythropoietin resistance in patients with CKD undergoing hemodialysis. This relationship suggests the need to explore whether telomere length recovery improves the response to ESAs.</jats:p>","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40244253","pmcid":null,"openalex_id":"https://openalex.org/W4409568031","authors":[],"funders":[],"total_grants":0,"fwci":1.3283,"citation_percentile":0.78635324,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1422-0067/26/7/3405/pdf?version=1744010675","host_type":"journal"},{"url":"https://www.mdpi.com/1422-0067/26/7/3405/pdf?version=1744010675","host_type":"publisher"},{"url":"https://www.mdpi.com/1422-0067/26/7/3405/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ijms26073405","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40244253","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11989996","host_type":"repository"}],"fields_of_study":["Telomeres, Telomerase, and Senescence","Mesenchymal stem cell research"],"mesh_terms":["Adult","Aged","Anemia","Cross-Sectional Studies","Drug Resistance","Erythropoietin","Female","Hematinics","Renal Dialysis","Humans","Male","Middle Aged","Telomere","Renal Insufficiency, Chronic","Telomere Shortening"],"keywords":["Erythropoietin","Medicine","Hemodialysis","Telomere","Internal medicine","Kidney disease","Hematocrit","Erythropoiesis","Anemia","Gastroenterology","Nephrology","Endocrinology","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T10:59:33.387704Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}